Journal Mobile Options
Table of Contents
Vol. 80, No. 4, 2013
Issue release date: October 2013

Residual β-Cell Mass Influences Growth of Prepubertal Children With Type 1 Diabetes

Bizzarri C. · Benevento D. · Patera I.P. · Bongiovanni M. · Boiani A. · Fusco C. · Cianfarani S. · Cappa M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: The growth deceleration observed in children with type 1 diabetes (T1D) has been related to poor glycemic control. It is unclear whether growth impairment persists despite the optimization of therapy. We analyzed the effects of intensive insulin treatment on prepubertal growth. Methods: One hundred and four T1D children were evaluated from T1D diagnosis up to puberty onset. Height, weight, insulin requirement and glycated hemoglobin (HbA1c) were recorded at 3- to 6-month intervals. Residual β-cell mass was estimated by fasting C-peptide at T1D onset. Results: Age at T1D onset was 5.91 ± 1.9 years. Follow-up duration was 4.84 ± 1.58 years. Height velocity standard deviation score (SDS) was -0.14 ± 1.84. Height SDS changed from 0.52 ± 1.04 at T1D onset, to 0.36 ± 1.10 at the end of follow-up (p = 0.04). BMI SDS increased from -0.04 ± 1.48 to 0.32 ± 1.03 (p = 0.01). Multivariate analysis showed that height velocity was directly affected by C-peptide (p = 0.03) and insulin requirement (p = 0.004) and inversely related to HbA1c (p = 0.006). BMI gain was negatively influenced by HbA1c (p = 0.01) and positively related to T1D duration (p = 0.01). Conclusion: Despite insulin intensive therapy, T1D still negatively affects growth. Residual β-cell mass has a direct positive impact on growth, independently from the quality of glycemic control.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Mauras N, Merimee T, Rogol AD: Function of the growth hormone insulin-like growth factor 1 axis in the profoundly growth-retarded diabetic child: evidence for defective target organ responsiveness in the Mauriac syndrome. Metabolism 1991;10:1106-1111.
  2. Tamborlane WV, Bonfig W, Boland E: Recent advances in treatment of youth with type 1 diabetes: better care through technology. Diabet Med 2001;18:864-870.
  3. Blom L, Persson LA, Dahlquist G: A high linear growth is associated with an increased risk of childhood diabetes mellitus. Diabetologia 1992;35:528-533.
  4. Bognetti E, Riva MC, Bonfanti R, Meschi F, Viscardi M, Chiumello G: Growth changes in children and adolescents with short-term diabetes. Diabetes Care 1998;21:1226-1229.

    External Resources

  5. Ljungkrantz M, Ludvigsson J, Samuelsson U: Type 1 diabetes: increased height and weight gains in early childhood. Pediatr Diabetes 2008;9:50-56.
  6. Cianfarani S, Bonfanti R, Manca Bitti ML, Germani S, Boemi S, Chiumello G, Boscherini B: Growth and insulin-like growth factors in children with insulin-dependent diabetes mellitus at the onset of disease: evidence for normal growth, age dependency of the IGF system alterations, and presence of a small (approximately 18-kilodalton) IGF-binding protein-3 fragment in serum. J Clin Endocrinol Metab 2000;85:4162-4167.
  7. Du Caju MV, Rooman RP, op de Beeck L: Longitudinal data on growth and final height in diabetic children. Pediatr Res 1995;38:607-611.
  8. Cacciari E, Milani S, Balsamo A, Dammacco F, De Luca F, Chiarelli F, Pasquino AM, Tonini G, Vanelli M: Italian cross-sectional growth charts for height, weight and BMI (6-20 y). Eur J Clin Nutr 2002;56:171-180.
  9. Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170-179.

    External Resources

  10. Tanner JM, Goldstein H, Whitehouse RH: Standards for children's height at ages 2-9 years allowing for heights of parents. Arch Dis Child 1970;45:755-762.

    External Resources

  11. Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303.

    External Resources

  12. Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-23.

    External Resources

  13. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group: Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971.
  14. Steffes MW, Sibley S, Jackson M, Thomas W: β-Cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003;26:832-836.

    External Resources

  15. Maes M, Underwood LE, Ketelslegers JM: Low serum somatomedin-C in insulin-dependent diabetes: evidence for a post receptor mechanism. Endocrinology 1986;118:377-382.

    External Resources

  16. Cotterill AM, Cowell CT, Silink M: Insulin and variation in glucose levels modify the secretion rates of the growth hormone independent insulin-like growth factor binding protein-1 in the human hepatoblastoma cell line Hep G2. J Endocrinol 1989;12:R17-R20.

    External Resources

  17. Johnson TR, Blossey BK, Denko CW, Ilan J: Expression of insulin-like growth factor I in cultured rat hepatocytes: effects of insulin and growth hormone. Mol Endocrinol 1989;3:580-587.
  18. Houston B, O'Neill IE: Insulin and growth hormone act synergistically to stimulate insulin-like growth factor-I production by cultured chicken hepatocytes. J Endocrinol 1991;128:389-393.

    External Resources

  19. Boni-Schnetzler M, Schmid C, Meier PJ, Froesch ER: Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Physiol 1991;260:E846-E851.

    External Resources

  20. Bornfeldt KE, Skottner A, Arnqvist HJ: In-vivo regulation of messenger RNA encoding insulin-like growth factor-I (IGF-I) and its receptor by diabetes, insulin and IGF-I in rat muscle. J Endocrinol 1992;135:203-211.

    External Resources

  21. Holly JM, Dunger DB, Edge JA, Smith CP, Chard T, Wass JA: Insulin-like growth factor binding protein-1 levels in diabetic adolescents and their relationship to metabolic control. Diabet Med 1990;7:618-623.
  22. Dunger DB, Cheetham TD: Growth hormone insulin-like growth factor I axis in insulin-dependent diabetes mellitus. Horm Res 1996;46:2-6.

    External Resources

  23. Amiel SA, Sherwin RS, Hintz RL, Gertner JM, Press CM, Tamborlane WV: Effect of diabetes and its control on insulin-like growth factors in the young subject with type-1 diabetes. Diabetes 1984;33:1175-1179.

    External Resources

  24. Taylor AM, Dunger DB, Grant DB, Preece MA: Somatomedin-C/IGF-I measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin-dependent diabetes compared with puberty matched controls. Diabetes Res 1988;9:177-181.

    External Resources

  25. Bereket A, Lang CH, Blethen SL, Gelato MC, Fan J, Frost RA, Wilson TA: Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995;80:1312-1317.
  26. Strasser-Vogel B, Blum WF, Past R, Kessler U, Hoeflich A, Meiler B, Kiess W: Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment. J Clin Endocrinol Metab 1995;80:1207-1213.
  27. Tapanainen P, Kaar ML, Leppaluoto J, Huttunen NP, Knip M: Normal stimulated growth hormone but low peripheral levels of insulin-like growth factor I in pre-pubertal children with insulin-dependent diabetes mellitus. Acta Paediatr 1995;84:646-650.
  28. Munoz MT, Barrios V, Pozo J, Argente J: Insulin-like growth factor-I, its binding proteins-1, and -3, and growth hormone binding protein in children and adolescents with insulin-dependent diabetes mellitus: clinical implications. Pediatr Res 1996;39:992-998.
  29. Radetti G, Paganini C, Antoniazzi F, Pasquino B, Valentini R, Gentili L, Tatò L: Growth hormone-binding proteins, IGF-I and IGF-binding proteins in children and adolescents with type 1 diabetes mellitus. Horm Res 1997;47:110-115.

    External Resources

  30. Chiarelli F, Giannini C, Mohn A: Growth, growth factors and diabetes. Eur J Endocrinol 2004;151(suppl 3):U109-U117.
  31. Bonfig W, Kapellen T, Dost A, Fritsch M, Rohrer T, Wolf J, Holl RW, et al: Growth in children and adolescents with type 1 diabetes. J Pediatr 2012;160:900-903.
  32. Taler I, Phillip M, Lebenthal Y, de Vries L, Shamir R, Shalitin S: Growth and metabolic control in patients with type 1 diabetes and celiac disease: a longitudinal observational case-control study. Pediatr Diabetes 2012;13:597-606.
  33. Knerr I, Wolf J, Reinehr T, Stachow R, Grabert M, Schober E, Rascher W, Holl RW, DPV Scientific Initiative of Germany and Austria: The ‘accelerator hypothesis': relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. Diabetologia 2005;48:2501-2504.
  34. Wilkin TJ: The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 2001;4:914-922.
  35. Malone JI: Growth and sexual maturation in children with insulin-dependent diabetes mellitus. Curr Opin Pediatr 1993;5:494-498.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50